SecProbe.io

Filing text and metadata
Intelligence Terminal Search Probe Scores Topics IPO Watchlist Monthly Activity About API

SEC Comment Letter for IMAC Holdings, Inc. (BACK) (CIK 0001729944) (BACK) — Apr 2, 2020

IMAC Holdings, Inc. (BACK) (CIK 0001729944)
Date: April 2, 2020 · CIK: 0001729944 · Accession: 0000000000-20-002859

AI Filing Summary & Sentiment

File numbers found in text: 333-237455

Date
April 2, 2020
Author
Not clearly detected
Form
UPLOAD
Company
IMAC Holdings, Inc. (BACK) (CIK 0001729944)

Letter

April 2, 2020 Jeffrey S. Ervin Chief Executive Officer IMAC Holdings, Inc. 1605 Westgate Circle Brentwood, Tennessee 37027 Re:IMAC Holdings, Inc. Registration Statement on Form S-3 Filed March 27, 2020 File No. 333-237455 Dear Mr. Ervin: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Irene Paik at 202-551-6553 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Spencer G. Feldman, Esq.

Show Raw Text
April 2, 2020
Jeffrey S. Ervin
Chief Executive Officer
IMAC Holdings, Inc.
1605 Westgate Circle
Brentwood, Tennessee 37027
Re:IMAC Holdings, Inc.
Registration Statement on Form S-3
Filed March 27, 2020
File No. 333-237455
Dear Mr. Ervin:
            This is to advise you that we have not reviewed and will not review your registration
statement.
            Please refer to Rules 460 and 461 regarding requests for acceleration.  We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
            Please contact Irene Paik at 202-551-6553 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:       Spencer G. Feldman, Esq.